Smart Medical Devices Market Size to Reach $180.4 Billion by 2033 - Strategic Growth Opportunities in Chronic Disease Management, Digital Health, and Connected Care
AUSTIN, Texas and TOKYO, Sept. 19, 2025 /PRNewswire/ -- The Smart Medical Devices Market Size valued at US$ 61.7 billion in 2024, is projected to reach US$ 180.4 billion by 2033, expanding at a CAGR of 12.8% (2025–2033), according to the latest report from DataM Intelligence.
Smart medical devices are rapidly transforming healthcare delivery, driven by rising chronic disease prevalence, aging populations, and the integration of AI, IoT, and connected therapeutics into clinical practice.
Download FREE Exclusive Sample Report: https://www.datamintelligence.com/download-sample/smart-medical-devices-market
Browse in-depth TOC on 'Smart Medical Devices Market'
62 – Tables
56 – Figures
159 – Pages
Market Drivers and Corporate Implications
Chronic Disease Burden
Cardiovascular diseases, diabetes, cancer, and respiratory illnesses account for 74% of global deaths annually (WHO).
Devices such as Abbott's FreeStyle Libre, Dexcom G7, and Medtronic's MiniMed insulin pumps highlight how digital therapeutics are enabling better outcomes and reducing hospital visits.
Digital Health & Connected Care
FDA approvals for CGM systems, smart insulin pumps, and wearable ECG monitors (Apple Watch, AliveCor) demonstrate regulatory support for innovation.
Adoption of telehealth and home-care solutions has accelerated, positioning smart medical devices as a cornerstone of next-gen healthcare delivery.
Regional Momentum
North America dominates with a 41.3% revenue share in 2024, underpinned by strong FDA pipelines and payer adoption.
Asia-Pacific is the fastest-growing region (CAGR 12.7%), fueled by digital health investments, chronic disease prevalence, and cost-effective manufacturing.
Europe benefits from MDR-driven compliance, an aging population, and partnerships between medtech startups and healthcare systems.
Strategic Opportunities for MedTech & Biopharma
Licensing & Partnerships: Collaboration opportunities between tech firms (Apple, Samsung) and medtech leaders (Abbott, Medtronic, Philips) to expand ecosystem integration.
Outsourcing & CDMOs: Demand for specialized manufacturing and connected-device platforms creates opportunities for medtech-focused contract partners.
Therapeutic Expansion: Beyond diabetes and cardiology, growth areas include respiratory, neurology, and sleep management devices.
Investment Hotspots: APAC offers cost-competitive innovation hubs, while North America leads in high-value reimbursement markets.
Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/smart-medical-devices-market
Market Segmentation Insights
By Product Type
Diagnostics and Monitoring Devices dominated the market in 2024, generating revenues of over US$ 40 billion. Products like smart wearable ECG monitors, glucose monitoring devices, and AI-powered diagnostic imaging solutions are driving this growth. The demand for continuous monitoring in chronic conditions such as diabetes and cardiac disorders has made this segment the backbone of the industry.
Therapeutic Devices, valued at US$ 21.6 billion in 2024, are witnessing rising adoption in pain management, neurology, and sleep therapy. Smart infusion pumps, insulin delivery systems, and neuromodulation devices are creating new revenue streams by improving therapy adherence and precision dosing.
By Application
- Cardiology accounted for the largest share in 2024 (US$ 15.8 billion), driven by the rising burden of cardiovascular diseases and adoption of remote monitoring solutions.
- Diabetes Management devices generated US$ 12.4 billion, with continuous glucose monitoring systems leading adoption in the U.S. and Asia-Pacific.
- Neurology and Sleep Disorder devices, valued collectively at US$ 10 billion, are gaining traction through wearable EEG monitors, sleep apnea detectors, and brain stimulation technologies.
- Pain Management and Others, at US$ 8.2 billion, are seeing faster adoption in homecare settings with smart TENS devices and connected therapeutic solutions.
By End-User
Hospitals remained the dominant end-user segment in 2024, with revenues of over US$ 27 billion, as smart devices become central to in-patient diagnostics and acute care.
Homecare Settings, however, are the fastest-growing category, valued at US$ 14 billion in 2024, propelled by telemedicine, remote monitoring, and patient demand for personalized healthcare solutions. Specialty clinics and ambulatory surgical centers collectively contributed US$ 20 billion, with increasing usage of portable monitoring and therapeutic devices.
Regional Highlights: USA and Japan
United States
The U.S., valued at over US$ 22 billion in 2024, is the largest market for smart medical devices, driven by high healthcare spending and digital health adoption. Recent trends include:
- Integration with telehealth platforms, enabling seamless patient monitoring beyond hospitals.
- FDA approvals for AI-based diagnostic tools and smart insulin delivery systems, boosting adoption.
- Major payers expanding reimbursement for connected devices, creating sustainable revenue channels.
Japan
Japan's market, valued at US$ 6.8 billion in 2024, is accelerating due to its aging population and government-driven healthcare digitization programs. Key highlights:
- Strong demand for remote monitoring of elderly patients with cardiovascular and diabetic conditions.
- Collaborations between global firms and Japanese hospitals to deploy AI-driven diagnostic devices.
- Japan's regulatory reforms in 2025 have simplified approval pathways for digital therapeutics and smart devices, boosting market entry.
Industry Trends & Recent Developments
- AI Integration: Companies like GE HealthCare and Philips are embedding AI in diagnostic imaging, improving accuracy and workflow efficiency.
- Wearables Boom: Apple and Samsung have expanded their healthcare device portfolios with advanced biosensors, targeting chronic care and preventive wellness markets.
- M&A Activity: In 2025, Abbott announced a strategic partnership with Dexcom to co-develop next-generation diabetes management devices, reinforcing market consolidation.
- Regulatory Acceleration: Both FDA (U.S.) and PMDA (Japan) have introduced fast-track approvals for connected devices that demonstrate strong clinical value.
Competitive Landscape
Abbott
Abbott leads in diabetes management and diagnostics, with its FreeStyle Libre continuous glucose monitoring system generating multi-billion-dollar revenues. In 2024, Abbott invested over US$ 2.8 billion in R&D, expanding into AI-powered cardiac monitoring solutions.
Medtronic
Medtronic reported US$ 32 billion in total revenues in 2024, with smart therapeutic and monitoring devices forming a key growth engine. The company is at the forefront of neuromodulation and smart insulin delivery technologies, partnering with AI startups to improve device intelligence.
Apple Inc.
Apple's healthcare wearables division surpassed US$ 5 billion in revenues in 2024, with the Apple Watch playing a central role in preventive care. The launch of AI-enabled health monitoring features in 2025-including sleep apnea detection and advanced arrhythmia alerts-has strengthened its leadership in consumer-driven medical devices.
Samsung Healthcare
Samsung's Galaxy Watch series is a market leader in Asia-Pacific for smart health monitoring. In 2025, the company integrated clinical-grade blood pressure monitoring into its wearables, positioning itself as a hybrid between consumer electronics and medical-grade devices.
F. Hoffmann-La Roche Ltd
Roche remains the global leader in next-generation antibodies, particularly ADCs. In 2024, its oncology antibody portfolio generated over US$ 6 billion, with Kadcyla and Polivy leading sales. The company continues to expand into bispecific antibodies targeting hematologic malignancies and is investing heavily in trispecific formats.
Amgen Inc.
Amgen reported ~US$ 28.2 billion in 2024 revenues, with next-gen antibodies forming a growing share. In 2025, Amgen secured FDA approval for a bispecific antibody in multiple myeloma, strengthening its hematology pipeline. Its strategy emphasizes accelerated clinical development, global licensing partnerships, and lifecycle management of established biologics.
Bristol-Myers Squibb (BMS)
BMS has established itself as a leader in immuno-oncology, with a diversified pipeline of bispecific antibodies and Fc-engineered products. In 2024, BMS invested US$ 11 billion in R&D, with a significant allocation to antibody therapeutics. Its strategic acquisition of a biotech firm specializing in antibody fragments reinforced its presence in rare disease applications.
Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=smart-medical-devices-market
Why This Matters for Executives:
For MedTech Strategy Teams: Identify product categories and regions driving the highest growth
For Investors: Track high-value therapeutic device approvals and digital health adoption trends
For Healthcare Providers & Payers: Evaluate how connected devices reduce costs and improve patient outcomes
Related Reports:
Request for Trial Access of AI-Driven Database Subscription Platform: https://www.datamintelligence.com/reports-subscription
Features of AI-Driven DataM Insights Database Subscription:
Track all your competitors in one centralized dashboard – From R&D, Investment, to marketing strategies, track your global and regional rivals with ease.
Competitive Intelligence – Stay ahead with detailed company profiling, SWOT analyses, and sales performance tracking.
Curated Industry News – Daily alerts keep teams informed about product innovation, M&A activity, and competitor moves.
Instant Report Access – Access the complete library of market reports across geographies.
Customizations Free of Charge – Get specific segments or competitor data added without paying extra.
Regional and Country-Level Insights – Get detailed views of market trends across the U.S., EU5, Japan, India, and LATAM.
Live Import/Export Data Access – Make informed decisions using real-time trade intelligence.
Contact:
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content: